Neurofilament light

A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion

Michael G Benatar, Joanne Wuu, Peter M. Andersen, Vittoria Lombardi, Andrea Malaspina

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). Methods: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. Results: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. Interpretation: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130–139.

Original languageEnglish (US)
Pages (from-to)130-139
Number of pages10
JournalAnnals of Neurology
Volume84
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Intermediate Filaments
Amyotrophic Lateral Sclerosis
Biomarkers
Light
Cerebrospinal Fluid
Signs and Symptoms
Serum
Asymptomatic Diseases
Natural History
Immunoassay
Disease Progression
Mutation
Population
Genes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Neurofilament light : A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. / Benatar, Michael G; Wuu, Joanne; Andersen, Peter M.; Lombardi, Vittoria; Malaspina, Andrea.

In: Annals of Neurology, Vol. 84, No. 1, 01.07.2018, p. 130-139.

Research output: Contribution to journalArticle

Benatar, Michael G ; Wuu, Joanne ; Andersen, Peter M. ; Lombardi, Vittoria ; Malaspina, Andrea. / Neurofilament light : A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. In: Annals of Neurology. 2018 ; Vol. 84, No. 1. pp. 130-139.
@article{2fd3043eccc1425abbd5154cfa103b1c,
title = "Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion",
abstract = "Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). Methods: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. Results: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. Interpretation: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130–139.",
author = "Benatar, {Michael G} and Joanne Wuu and Andersen, {Peter M.} and Vittoria Lombardi and Andrea Malaspina",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/ana.25276",
language = "English (US)",
volume = "84",
pages = "130--139",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Neurofilament light

T2 - A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion

AU - Benatar, Michael G

AU - Wuu, Joanne

AU - Andersen, Peter M.

AU - Lombardi, Vittoria

AU - Malaspina, Andrea

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). Methods: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. Results: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. Interpretation: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130–139.

AB - Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). Methods: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. Results: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. Interpretation: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130–139.

UR - http://www.scopus.com/inward/record.url?scp=85052588484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052588484&partnerID=8YFLogxK

U2 - 10.1002/ana.25276

DO - 10.1002/ana.25276

M3 - Article

VL - 84

SP - 130

EP - 139

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -